^
BIOMARKER:

STK11 mutation

i
Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant
:
B
ESMO 2022 - 3 weeks - (New B)
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
STK11 mutation
Non Small Cell Lung Cancer
nivolumab
Resistant
:
B
STK11 mutation
Non Small Cell Lung Cancer
DRP-104
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
durvalumab
Resistant
:
B
STK11 mutation
Non Small Cell Lung Cancer
atezolizumab
Resistant
:
B
STK11 mutation
Non Small Cell Lung Cancer
BGB324
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + BGB324
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive
:
B
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
docetaxel
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
rivoceranib + camrelizumab
Sensitive
:
C3
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab
Resistant
:
C3
STK11 mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant
:
C3
STK11 mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
STK11 mutation
Non Small Cell Lung Cancer
cetuximab + avelumab
Resistant
:
C3
STK11 mutation
Lung Adenocarcinoma
Immunotherapy
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab
Resistant
:
C3
STK11 mutation
Cervical Cancer
anlotinib + sintilimab
Resistant
:
C3
STK11 mutation
Solid Tumor
Immunotherapy
Resistant
:
C3
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant
:
C4
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive
:
C4
STK11 mutation
Pancreatic Cancer
everolimus
Sensitive
:
C4
STK11 mutation
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Resistant
:
C4
STK11 mutation
Lung Adenocarcinoma
abemaciclib
Sensitive
:
C4
STK11 mutation
Non Small Cell Lung Cancer
APG-115
Sensitive
:
D
STK11 mutation
Lung Cancer
dasatinib + selumetinib + RTB101
Sensitive
:
D
STK11 mutation
Lung Cancer
dasatinib
Resistant
:
D
STK11 mutation
Non Small Cell Lung Cancer
sirolimus
Sensitive
:
D
STK11 mutation
Non Small Cell Lung Cancer
CI-1040
Sensitive
:
D
STK11 mutation
Non Small Cell Lung Cancer
JQ-1
Resistant
:
D